曲妥珠单抗治疗进展后回顾性分析：机会均等问题。
Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities.
出版信息
Oncologist. 2011;16(4):534-6. doi: 10.1634/theoncologist.2010-0329. Epub 2011 Mar 10.
Abstract
Results of the Hermine study of trastuzumab beyond progression in breast cancer patients, published by Extra and colleagues in , are re-examined and an alternative explanation for the dismal postprogression survival time of patients stopping therapy is presented.
摘要
发表在《肿瘤学年鉴》上的 Extra 等人的文章重新审视了赫米恩研究中曲妥珠单抗在乳腺癌患者进展后的结果，并提出了一种替代方案来解释停止治疗后患者预后生存时间惨淡的原因。
相似文献
1
Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities.曲妥珠单抗治疗进展后回顾性分析：机会均等问题。
Oncologist. 2011;16(4):534-6. doi: 10.1634/theoncologist.2010-0329. Epub 2011 Mar 10.
2
Can cancer clinical trials be fixed?癌症临床试验能够得到改进吗？
Nat Biotechnol. 2011 Jan;29(1):13-5. doi: 10.1038/nbt.1746.
3
[Herceptin (trastuzumab)].赫赛汀（曲妥珠单抗）
Gan To Kagaku Ryoho. 2007 Aug;34(8):1173-6.
4
Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories.疾病进展后使用曲妥珠单抗：病例史回顾性研究的观察结果
Clin Breast Cancer. 2004 Apr;5(1):52-8; discussion 59-62. doi: 10.3816/cbc.2004.n.010.
5
Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.HER-2阳性转移性乳腺癌脑转移进展后继续使用曲妥珠单抗的临床效用
Oncologist. 2007 Dec;12(12):1467-9; author reply 1469-71. doi: 10.1634/theoncologist.12-12-1467.
6
[Do informed patients live longer?].[知情的患者寿命更长吗？]
Krankenpfl J. 2005;43(4-6):142-3.
7
Therapeutic monoclonal antibodies in oncology.肿瘤学中的治疗性单克隆抗体。
J R Soc Med. 2005 Apr;98(4):146-52. doi: 10.1177/014107680509800403.
8
Trastuzumab beyond progression: a challenge to translational oncology?曲妥珠单抗进展后治疗：对转化肿瘤学的挑战？
Ann Oncol. 2010 Nov;21(11):2131-2134. doi: 10.1093/annonc/mdq410. Epub 2010 Aug 23.
9
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.曲妥珠单抗在人表皮生长因子受体2（Her-2/neu）过表达的转移性乳腺癌中的疗效与p53状态无关。
J Cancer Res Clin Oncol. 2005 Jul;131(7):420-8. doi: 10.1007/s00432-005-0670-3. Epub 2005 Apr 29.
10
The incidence and treatment outcome after radiotherapy for brain metastases in HER-2-positive metastatic breast cancer patients treated with trastuzumab.接受曲妥珠单抗治疗的HER-2阳性转移性乳腺癌患者脑转移放疗后的发生率及治疗结果
Clin Oncol (R Coll Radiol). 2006 Nov;18(9):719-20. doi: 10.1016/j.clon.2006.07.006.
引用本文的文献
1
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?一种用于筛选和评估转移性疾病中抗癌药物成本与生存获益的新方法：成本是否应该纳入评估？
J Oncol Pract. 2012 Jul;8(4):224-30. doi: 10.1200/JOP.2011.000390.
本文引用的文献
1
Treatment beyond progression: is it moving from belief to evidence?进展后治疗：是否从信念走向证据？
Oncologist. 2010;15(8):796-8. doi: 10.1634/theoncologist.2010-0137. Epub 2010 Jul 29.
2
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.曲妥珠单抗在转移性乳腺癌患者常规临床实践及进展后的疗效：观察性 Hermine 研究。
Oncologist. 2010;15(8):799-809. doi: 10.1634/theoncologist.2009-0029. Epub 2010 Jul 29.
3
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.在基于曲妥珠单抗的治疗期间病情进展的HER2阳性晚期乳腺癌患者的结局
Oncologist. 2006 Apr;11(4):318-24. doi: 10.1634/theoncologist.11-4-318.
Zotero 插件